Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer, Inc. (Nasdaq: SEER), a prominent life sciences company specializing in proteomics, has announced its plans to release second quarter 2024 financial results on Thursday, August 8, 2024. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors and interested parties can access the live audio webcast through the Investor section of Seer's website at investor.seer.bio. An archived replay of the webcast will be made available on the company's website following the event for those unable to attend the live presentation.
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s technology allows comprehensive profiling of astronauts' physiological responses, aiding precision medicine and biomarker discovery. The studies include a substantial dataset from multiple space missions and highlight the Proteograph XT Assay Kit’s capabilities in detecting over 60,000 peptides and 8,000 proteins in plasma samples.
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample. The study, conducted across 77 clinical sites in the U.S., showcases the combined power of Seer and Thermo Fisher's technologies in early cancer detection. The findings will be presented at the ASMS Conference on June 6.
Seer, Inc. (Nasdaq: SEER), a life sciences company, reported Q1 2024 financial results. Achieved $3.1M in revenue, expanded STAC program to Europe, validated Proteograph Product Suite, launched Insights Grant Program, authorized $25M share repurchase program. Experienced a 24% revenue decrease primarily from product and related party revenue. Operating expenses decreased by 10%. Net loss was $20.7M. Cash position at $359.2M. Board authorized $25M share repurchase program. Full year revenue guidance for 2024 is $16-18M.
Seer, Inc. (Nasdaq: SEER) has launched a new Seer Technology Access Center in Bonn, Germany, to provide European life sciences researchers with access to the Seer Proteograph™ Product Suite and mass spectrometry technologies. The facility aims to support unbiased proteomic studies, accelerate biomarker discovery, and drug development. The European STAC will offer programs to enhance the availability of state-of-the-art proteomics technologies and assist researchers in expanding their research scope.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.